efficacy

Liposyn reports top-line safety and efficacy results for LPCN 1154 in patients with postpartum depression

by
(PRNewsfoto/Lipocine Inc.)

In a phase 3 study population of patients with PPD (N = 90), LPCN 1154 did not demonstrate a statistically significant reduction from baseline in the HAM-D17 total score at 60 hours (primary endpoint) compared to placebo. The primary endpoint was not met In a post hoc analysis of participants (n = 54) with a … Read more

PepGen announces excellent results from the low-dose (5 mg/kg) MAD cohort in the ongoing phase FREEDOM2 study, showing favorable safety, efficacy and vHOT data.

by
PepGen announces excellent results from the low-dose (5 mg/kg) MAD cohort in the ongoing phase FREEDOM2 study, showing favorable safety, efficacy and vHOT data.

– PGN-EDODM1 was generally well tolerated with all adverse events being mild or moderate and no serious adverse events reported – – Dissociation correction observed with PGN-EDODM1 (n=6) versus 6.8% with placebo (n=2); 7.3%; With the exception of one outpatient, the treatment group showed a mean improvement of 22.9% (n = 5). – A significant … Read more